FDA extends review of Novo Nordisk’s hemophilia A drug denecimig due to facility remediation
Novo Nordisk said the U.S. FDA has extended its review of the biologics license application for denecimig, a bispecific antibody for hemophilia A, because remediation work at the manufacturing site is still ongoing. The agency found no deficiencies in the submitted clinical efficacy or safety data. Novo maintains its 2026 financial outlook and still targets a U.S. launch in the first half of 2027.
Why it matters
The company’s statement that the delay does not affect its 2026 outlook suggests earnings expectations remain unchanged, but the later FDA decision pushes the earliest possible U.S. commercial start to 2027, which could defer revenue from the drug’s projected $2 billion annual sales.
Key facts
- 1The FDA review of denecimig remains ongoing with no new decision timeline communicated. tradingview.com
- 2The extension is caused by ongoing remediation activities at the manufacturing facility. tradingview.com
- 3The FDA identified no deficiencies in the clinical efficacy or safety data submitted. tradingview.com
- 4Novo originally expected an FDA decision in the third quarter of 2026. marketscreener.com
- 5Novo aims to launch denecimig in the United States in the first half of 2027, pending regulatory approval. tradingview.com
- 6Denecimig received a positive CHMP opinion on 17 September, with European marketing approval still pending. tradingview.com
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.